Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V8KD
|
|||
| Former ID |
DIB014766
|
|||
| Drug Name |
P-1101
|
|||
| Synonyms |
Pegylated interferon alpha (hepatitis B and C virus infection), PharmaEssentia; Pegylated interferon alpha-2b (polycythemia vera), AOP Orphan; PEG-INF-alpha (hepatitis B and C virus infection), PharmaEssentia; PEG-P-IFN-alpha-2b
Click to Show/Hide
|
|||
| Indication | Essential thrombocythemia [ICD-11: 3B63.1Z; ICD-9: 238.71, 289.9] | Phase 3 | [1] | |
| Hepatitis B virus infection [ICD-11: 1E51.0; ICD-10: B18.1] | Phase 3 | [2] | ||
| Myelofibrosis [ICD-11: 2A20.2; ICD-10: D47.4] | Phase 2 | [1] | ||
| Company |
Hanall biopharma; medtronic
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT01949805) Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera. U.S. National Institutes of Health. | |||
| REF 3 | Effects of PEG-interferon-alpha-2A on Schistosoma mansoni infection in mice. J Parasitol. 2010 Aug;96(4):703-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.